stockrowAbCellera Biologics Inc.
ABCL Healthcare Biotechnology
AbCellera Biologics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75.1 million, up 160.6% from fiscal 2024.
- Revenue
- −76.3%
- EPS
- −50.0%
- Free cash flow
- +152.0%
Quarter to June 2026, against a year earlier
Follow ABCL
Alert me
AbCellera Biologics Inc. (ABCL) Gross margin
AbCellera Biologics Inc.'s gross margin over the twelve months to 30 June 2026 was 100.0%, down 0.0 percentage points from fiscal 2025 (100.0%). Over the past ten years it has ranged from 100.0% (fiscal 2025) to 100.0% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 100.0% | 0.00 |
| FY2024 | 100.0% | 0.00 |
| FY2023 | 100.0% | 0.00 |
| FY2022 | 100.0% | 0.00 |
| FY2021 | 100.0% | 0.00 |
| FY2020 | 100.0% | 0.00 |
| FY2019 | 100.0% | 0.00 |
| FY2018 | 100.0% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Jun 2026 | 100.0% | 0.00 |
| Mar 2026 | 100.0% | 0.00 |
| Dec 2025 | 100.0% | 0.00 |
| Sep 2025 | 100.0% | 0.00 |
| 22 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| RLAY Relay Therapeutics, Inc. compare | 100.0% |
| ABCL AbCellera Biologics Inc. | 100.0% |
| TNGX Tango Therapeutics, Inc. compare | 100.0% |
| ARQT Arcutis Biotherapeutics, Inc. compare | 91.2% |
| ACAD ACADIA Pharmaceuticals Inc. compare | 90.5% |
| XENE Xenon Pharmaceuticals Inc. compare | 28.4% |
| IOVA Iovance Biotherapeutics, Inc. compare | 0.00% |
| EWTX Edgewise Therapeutics, Inc. compare | 0.00% |
| PBLS Parabilis Medicines, Inc. compare | — |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on ABCL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement